IL6 and prostate cancer: The predominant activation of trans-signaling IL6/soluble IL6R pathway in aggressive prostate cancer [45], together with the functional IL6R Asp358Ala influence in this mechanism, supports the increased risk for high-grade prostate cancer we observed for C carriers (Ala carriers).